A phase II proof-of-concept study of VR942 in inflammatory respiratory disease
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs VR 942 (Primary)
- Indications Respiratory tract disorders
- Focus Proof of concept; Therapeutic Use
- 21 Mar 2017 According to Vectura media release, company plans to initiate this study in H2 2017.
- 22 Nov 2016 According to a Vectura Group plc media release, this trial is scheduled to initiate in the first half of 2017.
- 26 May 2016 According to Vectura media release, company plans to initiate this study in 2017.